Latest news
Debiopharm Encourages Breakthough Cancer Research In Japan Through its Competitive JCA Mauvernay Award
6e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale
Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates
Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies
Debiopharm Collaborates With Innocentive For The Launch of A Global Challenge To Develop A Single-Dose mRNA Covid-19 Vaccine
Debiopharm Launches the “IDEAL” Initiative to Strengthen the Lemanic Region as a Hub for Life Science Innvovation
Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant
Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients
Le Challenge 2020 pour la qualité de vie du patient récompense le projet Oculus de sonnette connectée actionnée par le…
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.